StoneX Group’s Pacific Biosciences PACB Stock Holding History

StoneX Group’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$24K	Buy	+15,315	New	+$21.6K	﹤0.01%	1722

Other funds holding PACB

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Capricorn Fund Managers London, United Kingdom $1.06B AUM 45.98% 1-Year Est. Return

Carret Asset Management New York $1.14B AUM 25.06% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Advisornet Financial Minnetonka, Minnesota $2.21B AUM 14.38% 1-Year Est. Return

Koa Wealth Management Encinitas, California $154M AUM 13.16% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

StoneX Group's PACB Position: Q3 2026 in Review

StoneX Group opened a new position in Pacific Biosciences (PACB) in Q3 2026: 15,315 shares worth $24K. The stake represents ﹤0.01% of the portfolio and ranks #1722 among its holdings.

52 funds tracked by Wall St. Rank hold PACB as of Q3 2026.

StoneX Group held 15,315 shares of Pacific Biosciences worth $24K as of Q3 2026.
Pacific Biosciences was a new StoneX Group position in Q3 2026.
Pacific Biosciences made up ﹤0.01% of StoneX Group's portfolio in Q3 2026, its #1722 holding.
52 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2026.

Based on StoneX Group's 13F filing for Q3 2026, filed 3 Nov 2026.